Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.42 |
| ▸ | GCGR | P47871 | 2/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27793218 | 0.87 | MAPK14 (0.48) | MAPK14ALOX5MAPK13MAPK12MAPK11 | |
| SCHEMBL8387347 | 0.83 | TNK2 (0.46) | MAPK14ALOX5MAPK13MAPK12MAPK11 | |
| SCHEMBL8390603 | 0.83 | TNK2 (0.46) | MAPK14ALOX5MAPK13MAPK12MAPK11 | |
| SCHEMBL6930155 | 0.78 | MAPK14 (0.67) | MAPK14ALOX5MAPK13MAPK12MAPK11 | |
| SCHEMBL7354157 | 0.78 | MAPK14 (0.67) | MAPK14ALOX5MAPK13MAPK12MAPK11 | |
| SCHEMBL14838246 | 0.74 | CKS1B (0.46) | — | |
| SCHEMBL8310271 | 0.71 | MAPK14 (0.49) | MAPK14ALOX5MAPK13MAPK12MAPK11 | |
| SCHEMBL8309777 | 0.71 | MAPK14 (0.49) | MAPK14ALOX5MAPK13MAPK12MAPK11 | |
| SCHEMBL23410401 | 0.69 | GRIA1 (0.53) | MAPK14GRIA1 | |
| SCHEMBL23410469 | 0.68 | GRIA1 (0.52) | MAPK14ALOX5MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100098641-A1 | Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction | GILEAD SCIENCES, INC. | 2010-04-22 | — | — | US | disclosed |
| EP-2125841-A1 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF ANTI-INFLAMMATORY SIGNAL TRANSDUCTION MODULATORS (AISTM'S) AND BETA-AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION | Gilead Sciences, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008076265-A1 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF ANTI-INFLAMMATORY SIGNAL TRANSDUCTION MODULATORS (AISTM'S) AND β-AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098641-A1 | Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction | ADRB1, ADRB2, PDE11A | MAPK14 1362/4885ALOX5 1756/4885MAPK13 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.